# A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder

> **NCT06796868** · PHASE2 · COMPLETED · sponsor: **Beijing Greatway Pharmaceutical Technology Co.,Ltd.** · enrollment: 280 (actual)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** GW117 Tablets
- **DRUG:** GW117 Tablets
- **DRUG:** GW117 Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06796868
- **Lead sponsor:** Beijing Greatway Pharmaceutical Technology Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-10-12
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796868, "A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06796868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*